TMS Co (TSE:4891) Short Interest


TSE:4891 TMS Co Ltd TSE:4891
32 GF Score
Price 円103.00
! 1 Warning Sign
View Full Analysis

What is TMS Co Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

TSE:4891 vs VRTX, REGN, ALNY: Short Interest Comparison

For the Biotechnology subindustry, TMS Co's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TMS Co Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TMS Co's Short Interest distribution charts can be found below:

* The bar in red indicates where TMS Co's Short Interest falls into.


TSE:4891
32GF Score
TMS Co Ltd TSE:4891
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TMS Co Business Description

Address 1-9-11F, Fuchu-cho, Fuchu-shi, Tokyo, JPN, 183-0055
TMS Co Ltd is focused on researching, developing, manufacturing, and selling pharmaceuticals. The company is involved in conducting research and development of SMTP compounds, which are drug candidate substances targeting soluble epoxide hydrolase (sEH), an enzyme found in the human body. It is developing sEH inhibitors for various inflammatory diseases. The company's clinical pipeline comprises three compounds: TMS-007 (being developed as a potential treatment for acute cerebral infarction), which is in the late clinical stage, TMS-010, and JX09 (for resistant and poorly controlled hypertension) and TMS-008 (to target acute inflammatory diseases such as kidney injury and cancer cachexia), which are in the early clinical stage. In addition, it has TMS-009 as a backup compound for TMS-008.
32GF Score

Get the complete analysis for TSE:4891

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円103.00
Price